Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

SAN CARLOS, Calif. - Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company valued at $10.78 billion, has announced the commencement of the final stage of its Phase 2 study for VAX-31, a ...

接种肺炎链球菌疫苗，是防范肺炎的主要措施之一。如果咳嗽持续超过三周没有明显好转，患者应该看专科医生和接受胸部X光检查，以确定没有患上肺炎或其他严重肺病。 临床上使用的肺炎球菌疫苗有两种，即肺炎球菌多糖疫苗（Pneumococcal Polysaccharide Vaccine，简称PPSV）和肺炎球菌结合疫苗（Pneumococcal Conjugate Vaccine，简称PCV） 。

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...

Many nursing home residents are refusing COVID shots this winter, though flu vaccine penetration has remained strong historically.

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...